The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. / Rosager, Ann Mari; Dahlrot, Rikke H.; Sørensen, Mia D.; Bangsø, Julie A.; Hansen, Steinbjørn; Kristensen, Bjarne W.

I: Journal of Neuropathology and Experimental Neurology, Bind 81, Nr. 1, 2022, s. 54-60.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Rosager, AM, Dahlrot, RH, Sørensen, MD, Bangsø, JA, Hansen, S & Kristensen, BW 2022, 'The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients', Journal of Neuropathology and Experimental Neurology, bind 81, nr. 1, s. 54-60. https://doi.org/10.1093/jnen/nlab124

APA

Rosager, A. M., Dahlrot, R. H., Sørensen, M. D., Bangsø, J. A., Hansen, S., & Kristensen, B. W. (2022). The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. Journal of Neuropathology and Experimental Neurology, 81(1), 54-60. https://doi.org/10.1093/jnen/nlab124

Vancouver

Rosager AM, Dahlrot RH, Sørensen MD, Bangsø JA, Hansen S, Kristensen BW. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. Journal of Neuropathology and Experimental Neurology. 2022;81(1):54-60. https://doi.org/10.1093/jnen/nlab124

Author

Rosager, Ann Mari ; Dahlrot, Rikke H. ; Sørensen, Mia D. ; Bangsø, Julie A. ; Hansen, Steinbjørn ; Kristensen, Bjarne W. / The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. I: Journal of Neuropathology and Experimental Neurology. 2022 ; Bind 81, Nr. 1. s. 54-60.

Bibtex

@article{a03ec504ce1448c2978001e3e495c0e8,

title = "The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients",

abstract = "Patients with IDH-wildtype glioblastoma (GBM) generally have a poor prognosis. However, there is an increasing need of novel robust biomarkers in the daily clinico-pathological setting to identify and support treatment in patients who become long-time survivors. Jumonji domain-containing protein 6 (JMJD6) is involved in epigenetic regulation of demethylation of histones and has been associated with GBM aggressiveness. We investigated the expression and prognostic potential of JMJD6 tumor fraction score in 184 IDH-wildtype GBMs. Whole-slides were double-stained with an antibody against JMJD6 and an exclusion-cocktail consisting of 4 antibodies (CD31, SMA, CD45, and Iba-1), enabling evaluation of tumor cells only. Stainings were quantified with a combined software- and scoring-based approach. For comparison, IDH-mutated WHO grade II, III and IV astrocytic gliomas were also stained, and the JMJD6 tumor fraction score increased with increasing WHO grade, although not significantly. In multivariate analysis including age, gender, performance status and post-surgical treatment high JMJD6 tumor fraction score was associated with longer overall survival in IDH-wildtype GBMs (p = 0.03), but the effect disappeared when MGMT promoter status was included (p = 0.34). We conclude that JMJD6 is highly expressed in IDH-wildtype GBM but it has no independent prognostic value.",

keywords = "Brain tumor, Glioma, Jumonji domain-containing protein 6, Microglia, Prognostic, Tumor stem cell",

author = "Rosager, {Ann Mari} and Dahlrot, {Rikke H.} and S{\o}rensen, {Mia D.} and Bangs{\o}, {Julie A.} and Steinbj{\o}rn Hansen and Kristensen, {Bjarne W.}",

year = "2022",

doi = "10.1093/jnen/nlab124",

language = "English",

volume = "81",

pages = "54--60",

journal = "Journal of Neuropathology and Experimental Neurology",

issn = "0022-3069",

publisher = "Oxford University Press",

number = "1",

}

RIS

TY - JOUR

T1 - The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients

AU - Rosager, Ann Mari

AU - Dahlrot, Rikke H.

AU - Sørensen, Mia D.

AU - Bangsø, Julie A.

AU - Hansen, Steinbjørn

AU - Kristensen, Bjarne W.

PY - 2022

Y1 - 2022

N2 - Patients with IDH-wildtype glioblastoma (GBM) generally have a poor prognosis. However, there is an increasing need of novel robust biomarkers in the daily clinico-pathological setting to identify and support treatment in patients who become long-time survivors. Jumonji domain-containing protein 6 (JMJD6) is involved in epigenetic regulation of demethylation of histones and has been associated with GBM aggressiveness. We investigated the expression and prognostic potential of JMJD6 tumor fraction score in 184 IDH-wildtype GBMs. Whole-slides were double-stained with an antibody against JMJD6 and an exclusion-cocktail consisting of 4 antibodies (CD31, SMA, CD45, and Iba-1), enabling evaluation of tumor cells only. Stainings were quantified with a combined software- and scoring-based approach. For comparison, IDH-mutated WHO grade II, III and IV astrocytic gliomas were also stained, and the JMJD6 tumor fraction score increased with increasing WHO grade, although not significantly. In multivariate analysis including age, gender, performance status and post-surgical treatment high JMJD6 tumor fraction score was associated with longer overall survival in IDH-wildtype GBMs (p = 0.03), but the effect disappeared when MGMT promoter status was included (p = 0.34). We conclude that JMJD6 is highly expressed in IDH-wildtype GBM but it has no independent prognostic value.

AB - Patients with IDH-wildtype glioblastoma (GBM) generally have a poor prognosis. However, there is an increasing need of novel robust biomarkers in the daily clinico-pathological setting to identify and support treatment in patients who become long-time survivors. Jumonji domain-containing protein 6 (JMJD6) is involved in epigenetic regulation of demethylation of histones and has been associated with GBM aggressiveness. We investigated the expression and prognostic potential of JMJD6 tumor fraction score in 184 IDH-wildtype GBMs. Whole-slides were double-stained with an antibody against JMJD6 and an exclusion-cocktail consisting of 4 antibodies (CD31, SMA, CD45, and Iba-1), enabling evaluation of tumor cells only. Stainings were quantified with a combined software- and scoring-based approach. For comparison, IDH-mutated WHO grade II, III and IV astrocytic gliomas were also stained, and the JMJD6 tumor fraction score increased with increasing WHO grade, although not significantly. In multivariate analysis including age, gender, performance status and post-surgical treatment high JMJD6 tumor fraction score was associated with longer overall survival in IDH-wildtype GBMs (p = 0.03), but the effect disappeared when MGMT promoter status was included (p = 0.34). We conclude that JMJD6 is highly expressed in IDH-wildtype GBM but it has no independent prognostic value.

KW - Brain tumor

KW - Glioma

KW - Jumonji domain-containing protein 6

KW - Microglia

KW - Prognostic

KW - Tumor stem cell

U2 - 10.1093/jnen/nlab124

DO - 10.1093/jnen/nlab124

M3 - Journal article

C2 - 34875075

AN - SCOPUS:85123813444

VL - 81

SP - 54

EP - 60

JO - Journal of Neuropathology and Experimental Neurology

JF - Journal of Neuropathology and Experimental Neurology

SN - 0022-3069

IS - 1

ER -

ID: 291992461

Institut for Klinisk Medicin